CosmoFarm Hits $60M+ Annualized Revenue, 4.3x Growth; AI and Robotics Pave Path to $100M
COSM has more than doubled off its 52-week low of $0.162 on light trading volume (0.1× avg).
Summary
Cosmos Health's pharmaceutical distribution subsidiary CosmoFarm reached a record annualized revenue run-rate above $60 million, up 4.3x since acquisition, driven by a 3.6x increase in daily-served pharmacies and 19% higher revenue per pharmacy. The company is deploying robotics and AI to expand capacity to support over $100 million in annualized revenue, with a letter of intent signed for its largest acquisition yet—a network generating about €10 million annually. This follows a Q2 loss that more than doubled to $6.09M with going concern doubt, making CosmoFarm's growth a critical offset. The update provides concrete operational traction toward the 2029 guidance of $200.6M revenue, but execution on the pending acquisition and margin improvement remain key.
At the time of this announcement, COSM was trading at $0.39 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $39.5M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.